7-(4-nitrophenylcarbonate)paclitaxel | 1151990-43-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 7-(4-nitrophenylcarbonate)paclitaxel
• 英文别名: 7-(p-nitrophenyl carbonate) paclitaxel；[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1-hydroxy-10,14,17,17-tetramethyl-9-(4-nitrophenoxy)carbonyloxy-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
• CAS: 1151990-43-0
• 化学式: C₅₄H₅₄N₂O₁₈
• 分子量: 1019.03
• InChiKey: BPPUGDOPZOKSKR-PUFPEYIYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  74
• 可旋转键数：
  18
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  282
• 氢给体数：
  3
• 氢受体数：
  18

反应信息

• 作为反应物：
  描述：

  7-(4-nitrophenylcarbonate)paclitaxel 、 18-[p-(4-aminobutylamido)phenyl]octadecyl phosphocholine 在 吡啶 作用下， 以 氯仿 为溶剂， 反应 5.0h， 以86%的产率得到
  参考文献：
  名称：

  Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles

  摘要：

  本发明旨在针对癌细胞和癌干细胞的治疗化合物。本发明进一步涉及包含这些治疗化合物的组合物和治疗癌症的方法，其中包括给予这些治疗化合物。

  公开号：

  US20160136190A1
• 作为产物：
  描述：

  2',7-(4-nitrophenylbiscarbonate)paclitaxel 在 silica gel 作用下， 以 氯仿 为溶剂， 反应 72.0h， 以53%的产率得到7-(4-nitrophenylcarbonate)paclitaxel
  参考文献：
  名称：

  Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles

  摘要：

  本发明旨在针对癌细胞和癌干细胞的治疗化合物。本发明进一步涉及包含这些治疗化合物的组合物和治疗癌症的方法，其中包括给予这些治疗化合物。

  公开号：

  US20160136190A1

文献信息

• Preparation and characterization of novel poly(ethylene glycol) paclitaxel derivatives
  作者：Silvia Arpicco、Barbara Stella、Oddone Schiavon、Paola Milla、Daniele Zonari、Luigi Cattel

  DOI：10.1016/j.ijpharm.2013.05.027

  日期：2013.10

  Paclitaxel has been found to be very effective against several human cancers; one of the major problems with its use is its poor solubility, which makes necessary its solubilization with excipients that can determine allergic reactions often severe. The aim of this study is to develop highly water-soluble prodrugs of paclitaxel. For this purpose we prepared a series of new paclitaxel-poly(ethylene glycol) (PEG) conjugates that were characterized and evaluated for their in vitro stability and cytotoxicity. In particular, in order to modulate the release of paclitaxel from prodrugs, we prepared different compounds introducing PEG in the drug C2' and/or C7 positions via ester or carbamate linkage. The conjugates were obtained in high purity and good yield. The carbamate prodrugs were highly stable in different media, while the compounds obtained linking PEG at C2' position through an ester bond showed lower stability. Finally, the cytotoxic activity of the conjugates was evaluated on two cancer cell lines and the results showed that all the derivatives had a reduced cytotoxicity compared to that of paclitaxel. (C) 2013 Elsevier B. V. All rights reserved.
• US9345718B1
  申请人：——

  公开号：US9345718B1

  公开（公告）日：2016-05-24
• US9480754B2
  申请人：——

  公开号：US9480754B2

  公开（公告）日：2016-11-01
• US9925269B2
  申请人：——

  公开号：US9925269B2

  公开（公告）日：2018-03-27